Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Enanta Pharmaceuticals, Inc

ENTA

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Last trade $9.24
Day change -$1.43 (-13.40%)
Day range $8.82 – $10.99
Volume 572,473
Market cap $311M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$310.77M
Price / earnings
—
Price / book
3.07×
Price / sales
4.76×
EV / sales
4.25×
EV / EBITDA
-5.15×

Profitability

Earnings per share
-$2.17
Return on assets
-21.3%
Return on equity
-62.56%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.76×
Quick ratio
3.76×
Cash ratio
0.62×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$36.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ENTA, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$14.36M$17.16M$18.62M$15.13M$18.31M$14.93M$16.96M$14.61M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$14.36M$17.16M$18.62M$15.13M$18.31M$14.93M$16.96M$14.61M
Selling, general and administrative$9.47M$9.57M$9.01M$9.7M$10M$11.39M$12.85M$13.68M
Research and development$22.13M$19.44M$20.86M$23.81M$27.21M$28.07M$27.66M$30.78M
Total operating expenses$31.6M$29.01M$29.87M$33.51M$37.21M$39.45M$40.5M$44.46M
Operating income-$17.24M-$11.85M-$11.25M-$18.39M-$18.89M-$24.53M-$23.54M-$29.85M
Interest expense-$4.13M-$3.32M-$3.08M-$2.39M-$1.62M-$1.71M-$1.96M-$2.58M
Income before taxes-$19.47M-$13.08M-$11.91M-$18.67M-$18.23M-$23.95M-$22.71M-$29.19M
Income taxes$36K$7K$24K$32K$29K-$1.31M-$416K-$363K
Net income-$19.5M-$13.09M-$11.94M-$18.7M-$18.26M-$22.64M-$22.29M-$28.82M
Net income attributable to common shareholders-$19.5M-$13.09M-$11.94M-$18.7M-$18.26M-$22.64M-$22.29M-$28.82M
EBITDA-$16.05M-$10.64M-$10.02M-$17.1M-$17.68M-$23.32M-$22.65M-$29.38M
Basic earnings per share-$0.67-$0.45-$0.42-$0.87-$0.85-$1.06-$1.05-$1.36
Diluted earnings per share-$0.67-$0.45-$0.42-$0.87-$0.85-$1.06-$1.05-$1.36

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals reported a Q4 loss of $0.81 per share, slightly beating the consensus estimate of $0.83 loss, but missed revenue expectations with $12.87 million versus the estimated $13.85 million. The company's stock has declined 30.3% year-to-date, significantly underperforming the S&P 500's 10.5% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting it will perform in line with the market.

Zacks Investment Research

BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Misses Revenue Estimates

BioHarvest Sciences Inc. (BHST) reported a Q3 loss of $0.15 per share, beating EPS estimates but missing revenue expectations with $7.87 million versus the consensus estimate. The company's stock has declined 66.3% year-to-date, significantly underperforming the S&P 500's 11.3% gain. BHST received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates

Immatics (IMTX) reported a quarterly loss of $0.58 per share, missing the consensus estimate of $0.49 by 18.37%, and posted revenues of $7.97 million, missing estimates by 22.12%. The stock has underperformed significantly, down 38.8% year-to-date compared to the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.